The French group Sanofi has announced that until the Zentiva plant in Bucharest will be sold, as part of the strategy to spin-off its generics drugs operations in Europe, the company will continue to operate as usual.
Emmanuelle Valentin, general manager of Sanofi in Romania, said: “Until the disposal of this activity that is expected to happen in 2018, we do not anticipate any significant changes nor impacts on our local commercial and industrial activities nor on our existing portfolios, including generics. We will continue to operate our business as usual and we will maintain our production and development plans for the Bucharest plant. We remain fully committed to delivering the best possible service to our customers and we are upholding our commitments towards Romanian patients’ needs.”
Sanofi, a global healthcare operator that discovers, develops and distributes therapeutic solutions focused on patients’ needs.
The company is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.